Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT

Fig. 2

Proportion of patients achieving ASAS40 response in the overall population through week 16. *P < 0.0001, †P < 0.001, §P < 0.01, ‡P < 0.05 versus placebo. Data presented as NRI through week 16. ASAS, Assessment of SpondyloArthritis international Society; CRP, C-reactive protein; MRI, magnetic resonance imaging; N, total number of patients; NRI, non-responder imputation

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us